Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
125.9 USD | -0.84% | -3.16% | -8.68% |
Apr. 11 | John Chevedden Files an Exempt Solicitation Statement with Securities and Exchange Commission | CI |
Apr. 05 | Quest Diagnostics Receives Shareholder Proposal from John Chevedden | CI |
Summary
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Healthcare Facilities & Services
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.68% | 13.98B | A- | ||
-12.12% | 87.46B | B- | ||
+9.72% | 78.56B | C+ | ||
+10.85% | 29.37B | C+ | ||
-12.25% | 16.78B | B | ||
-5.06% | 16.01B | A- | ||
+1.87% | 12.31B | A- | ||
-30.00% | 12.07B | - | - | |
+20.38% | 11.06B | B- | ||
-4.03% | 11.4B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- DGX Stock
- Ratings Quest Diagnostics Incorporated